Page 48 - AN-3-1

Advanced Neurology Antibodies as neurodegenerative biomarkers

opportunities. Nat Rev Neurol. 2020;16(10):529-546. 91. Sugimoto K, Mori M, Liu J, et al. Novel serum autoantibodies
against ß-actin (ACTB) in amyotrophic lateral sclerosis.
doi: 10.1038/s41582-020-0389-4
Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(5-
81. Bayram-Weston Z, Jones L, Dunnett SB, Brooks SP, et al. 6):388-394.
Comparison of mHTT antibodies in Huntington’s disease
mouse models reveal specific binding profiles and steady- doi: 10.1080/21678421.2021.1885448
state ubiquitin levels with disease development. PLoS One. 92. Domínguez-Fernández C, Egiguren-Ortiz J, Razquin J, et al.
2016;11(5):e0155834. Review of technological challenges in personalised medicine
and early diagnosis of neurodegenerative disorders. Int J Mol
doi: 10.1371/journal.pone.0155834
Sci. 2023;24(4):3321.
82. Lee DH, Heidecke H, Schröder A, et al. Increase of angiotensin
II type 1 receptor auto-antibodies in Huntington’s disease. doi: 10.3390/ijms24043321
Mol Neurodegener. 2014;9(1):49. 93. Gaetani L, Paolini Paoletti F, Bellomo G, et al. CSF and blood
biomarkers in neuroinflammatory and neurodegenerative
doi: 10.1186/1750-1326-9-49
diseases: Implications for treatment. Trends Pharmacol Sci.
83. Endres D, Werden R, Schweizer T, et al. Novel neuronal 2020;41(12):1023-1037.
autoantibodies in Huntington’s disease. Biol Psychiatry. doi: 10.1016/j.tips.2020.09.011
2022;91(4):e21-e23.
94. Diamond B, Honig G, Mader S, Brimberg L, Volpe BT.
doi: 10.1016/j.biopsych.2020.12.032
Brain-reactive antibodies and disease. Annu Rev Immunol.
84. Masrori P, Van Damme P. Amyotrophic lateral sclerosis: 2013;31(1):345-385.
A clinical review. Eur J Neurol. 2020;27(10):1918-1929.
doi: 10.1146/annurev-immunol-020711-075041
doi: 10.1111/ene.14393
95. Baril L, Nicolas L, Croisile B, et al. Immune response to
85. Tafuri F, Ronchi D, Magri F, Comi GP, Corti S. SOD1 Abeta-peptides in peripheral blood from patients with
misplacing and mitochondrial dysfunction in amyotrophic Alzheimer’s disease and control subjects. Neurosci Lett.
lateral sclerosis pathogenesis. Front Cell Neurosci. 2015;9:336. 2004;355(3):226-230.
doi: 10.3389/FNCEL.2015.00336 doi: 10.1016/j.neulet.2003.10.071
86. Conti E, Sala G, Diamanti S, et al. Serum naturally occurring 96. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L,
anti-TDP-43 auto-antibodies are increased in amyotrophic Szabo P. Patients with Alzheimer disease have lower levels of
lateral sclerosis. Sci Rep. 2021;11(1):1978. serum anti-amyloid peptide antibodies than healthy elderly
doi: 10.1038/s41598-021-81599-5 individuals. Exp Gerontol. 2002;37(7):943-948.
87. Nielsen AK, Folke J, Owczarek S, et al. TDP-43-specific doi: 10.1016/S0531-5565(02)00029-3
autoantibody decline in patients with amyotrophic 97. Qu BX, Gong Y, Moore C, et al. Beta-amyloid auto-antibodies
lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. are reduced in Alzheimer’s disease. J Neuroimmunol.
2021;8(2):e937. 2014;274(1-2):168-173.
doi: 10.1212/NXI.0000000000000937 doi: 10.1016/j.jneuroim.2014.06.017
88. Riemenschneider H, Simonetti F, Sheth U, et al. Targeting 98. Brettschneider S, Morgenthaler NG, Teipel SJ, et al.
the glycine-rich domain of TDP-43 with antibodies prevents Decreased serum amyloid beta(1-42) autoantibody levels
its aggregation in vitro and reduces neurofilament levels in in Alzheimer’s disease, determined by a newly developed
vivo. Acta Neuropathol Commun. 2023;11(1):112. immuno-precipitation assay with radiolabeled amyloid
beta(1-42) peptide. Biol Psychiatry. 2005;57(7):813-816.
doi: 10.1186/s40478-023-01592-z
doi: 10.1016/j.biopsych.2004.12.008
89. Atlasi RS, Malik R, Corrales CI, et al. Investigation of anti-
SOD1 antibodies yields new structural insight into SOD1 99. Song M, Mook-Jung I, Lee H, Min JY, Park MH. Serum anti-
misfolding and surprising behavior of the antibodies amyloid-beta antibodies and Alzheimer’s disease in elderly
themselves. ACS Chem Biol. 2018;13(9):2794-2807. Korean patients. J Int Med Res. 2007;35(3):301-306.
doi: 10.1021/acschembio.8b00729 doi: 10.1177/147323000703500303
90. Niebroj-Dobosz I, Dziewulska D, Janik P. Auto-antibodies 100. Nath A, Hall E, Tuzova M, et al. Autoantibodies to
against proteins of spinal cord cells in cerebrospinal fluid amyloid beta-peptide (Abeta) are increased in Alzheimer’s
of patients with amyotrophic lateral sclerosis (ALS). Folia disease patients and Abeta antibodies can enhance Abeta
Neuropathol. 2006;44(3):191-196. neurotoxicity: Implications for disease pathogenesis and

Volume 3 Issue 1 (2024) 13 https://doi.org/10.36922/an.2058